Aerovate Therapeutics Investor Relations Material
Latest events
Q1 2025
25 Apr, 2025
Q4 2024
27 Mar, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Aerovate Therapeutics Inc
Access all reports
Aerovate Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for rare cardiopulmonary diseases. The company's lead product candidate is AV-101, a dry powder inhaled formulation of imatinib, designed to treat pulmonary arterial hypertension (PAH). This formulation aims to deliver the drug directly to the lungs, targeting the underlying disease mechanisms while minimizing systemic side effects. Aerovate Therapeutics is headquartered in Waltham, Massachusetts, and its shares are listed on the NASDAQ.
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
AVTE
Country
🇺🇸 United States